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Novelty StatementWe suggest that MM patients are observed for increased vulnerability to adverse COVID‐19 outcomes during progression or under certain immunomodulatory therapies.Patients with progressive disease under daratumumab treatment and patients in remission on lenalidomide treatment may be at higher risk for mortality from COVID‐19.Patients with progressive MM under daratumumab treatment or in remission under lenalidomide treatment may need a closer clinical follow‐up during the current COVID‐19 pandemic.

1. INTRODUCTION {#ejh13502-sec-0002}
===============

The coronavirus disease 2019 (COVID‐19), caused by the coronavirus SARS‐CoV‐2, has become a global pandemic since its first emergence in late 2019. The clinical presentation varies among individuals with patients reporting only mild respiratory symptoms to severe lethal respiratory disease and multi‐organ damage.[^1^](#ejh13502-bib-0001){ref-type="ref"} Risk factors for a severe course of the disease and adverse outcome are increased age, male gender, obesity, and other comorbidities.[^2^](#ejh13502-bib-0002){ref-type="ref"} Cancer patients are at higher risk to develop a severe form of COVID‐19.[^3^](#ejh13502-bib-0003){ref-type="ref"} It is yet unclear whether the increased risk is associated with the malignancy, treatment strategies, or other possible iatrogenic factors.[^4^](#ejh13502-bib-0004){ref-type="ref"}

The introduction of new therapeutic agents, such as immunomodulatory drugs (IMIDs), proteasome inhibitors (PI), and monoclonal antibodies in the treatment of multiple myeloma (MM), lead to increased survival rates.[^5^](#ejh13502-bib-0005){ref-type="ref"} However, several of these novel treatments are associated with an increased risk of infectious complications.[^6^](#ejh13502-bib-0006){ref-type="ref"} We recently reported that MM patients receiving daratumumab were at increased risk for bacterial and viral infections.[^7^](#ejh13502-bib-0007){ref-type="ref"} Pathogenesis of MM results in the suppression of the adaptive immune system and leads to low levels of immunoglobulin production. Reduction of immunoglobulin levels is seen in more than 70% of patients with MM.[^8^](#ejh13502-bib-0008){ref-type="ref"} Such immunoparesis (hypogammaglobulinemia) is correlated with shorter overall survival (OS) and progression‐free survival (PFS).[^9^](#ejh13502-bib-0009){ref-type="ref"}

Treatment guidelines of cancer patients during the COVID‐19 pandemic have been published by several consensus groups such as the European Myeloma Network (EMN).[^10^](#ejh13502-bib-0010){ref-type="ref"} More studies are needed to define the risk groups among MM patients and to refine treatment recommendations. We therefore, here, assessed a cohort of patients that were previously diagnosed with MM or smoldering MM (SMM) and developed COVID‐19 during March to May 2020 in Stockholm.

2. METHODS AND RESULTS {#ejh13502-sec-0003}
======================

The characteristics of the nine patients followed are summarized in Table [1](#ejh13502-tbl-0001){ref-type="table"}. Of the patients, eight had MM and one patient had SMM. Six of the MM patients were on daratumumab‐based treatment and two of the patients were treated with lenalidomide‐dexamethasone (RD). All patients presented with fever and eight out of nine patients additionally reported dry cough. Other symptoms were dyspnea, arthralgia, diarrhea, and ageusia (loss of taste). Upon symptom onset, the MM treatments were discontinued. All patients were confirmed with COVID‐19 by PCR from nasopharyngeal swabs within 14 days after symptom debut. Four out of nine patients died within three weeks after initial symptoms (Table [1](#ejh13502-tbl-0001){ref-type="table"}). Of the deceased patients, two had progressive disease while on daratumumab, three weeks prior to initial symptoms. The other two deceased patients had received RD and were in remission at the time of COVID‐19 diagnosis. Among the patients that survived, the patient with SMM developed COVID‐19‐specific IgM antibodies within one week after the onset of the symptoms. However, no seroconversion to IgG occurred. Of the three other patients with MM that received daratumumab, only one patient developed an IgG response. All alive patients resolved their COVID‐19 symptoms and resumed their daratumumab‐based treatments, despite remaining SARS‐CoV‐2 PCR positive.

###### 

Patient characteristics, treatments, COVID‐19‐related outcomes as well as additional laboratory and clinical data

  Pat. ID                                                                    1                                             2                                             3                                             4                                              5                                             6                                            7                                              8                                            9
  -------------------------------------------------------------------------- --------------------------------------------- --------------------------------------------- --------------------------------------------- ---------------------------------------------- --------------------------------------------- -------------------------------------------- ---------------------------------------------- -------------------------------------------- ---------------------------------------------
  Patient characteristics, treatments and COVID‐19 related outcomes                                                                                                                                                                                                                                                                                                                                                                                          
  Diagnosis                                                                  MM                                            MM                                            MM                                            MM                                             MM                                            MM                                           MM                                             MM                                           SMM
  Age, y                                                                     58                                            77                                            70                                            70                                             43                                            83                                           94                                             71                                           68
  Gender                                                                     M                                             M                                             F                                             M                                              F                                             F                                            M                                              M                                            M
  Sub‐type                                                                   IgAλ                                          κ                                             IgAλ                                          IgGκ                                           IgAκ                                          IgAλ                                         IgDλ                                           IgGκ                                         IgGλ
  ISS[^a^](#ejh13502-note-0003){ref-type="fn"}                               III                                           III                                           III                                           II                                             ---                                           II                                           III                                            ---                                          II
  Previous lines of MM treatment                                             5[^b^](#ejh13502-note-0004){ref-type="fn"}    0                                             4[^c^](#ejh13502-note-0005){ref-type="fn"}    0                                              1[^d^](#ejh13502-note-0006){ref-type="fn"}    1[^e^](#ejh13502-note-0007){ref-type="fn"}   0                                              1[^f^](#ejh13502-note-0008){ref-type="fn"}   ---
  Current line of MM treatment                                               dD‐Veneto                                     dVD                                           dD                                            dRD                                            dKD                                           dD                                           RD                                             RD                                           None
  Months on current MM treatment                                             2                                             3                                             7                                             49                                             5                                             16                                           3                                              17                                           ---
  MM response to current line                                                PD                                            PD                                            MR                                            CR                                             VGPR                                          VGPR                                         PR                                             VGPR                                         ---
  MM disease progression                                                     Yes                                           Yes                                           No                                            No                                             No                                            No                                           No                                             No                                           No
  COVID‐19 related risk factors                                              DM2                                           No                                            No                                            No                                             DM2, HT                                       DM2, HT                                      DM2                                            No                                           HT
  BMI                                                                        30                                            23                                            20                                            21                                             24                                            34                                           25                                             24                                           23
  Anticoagulants                                                             No                                            No                                            No                                            Yes                                            No                                            No                                           Yes                                            Yes                                          No
  Death due to COVID‐19                                                      Yes                                           Yes                                           No                                            No                                             No                                            No                                           Yes                                            Yes                                          No
  Laboratory values at verification of COVID‐19 (PCR)                                                                                                                                                                                                                                                                                                                                                                                                        
  CRP, mg/L                                                                  79                                            16                                            38                                            136                                            \<1                                           65                                           ---                                            6                                            ---
  Hemoglobin, g/dL                                                           71                                            104                                           93                                            100                                            112                                           100                                          114                                            132                                          126
  Leukocytes, 10^9^/L                                                        1.2                                           10.5                                          6.1                                           4.9                                            2                                             4.3                                          4                                              1.8                                          5.2
  Neutrophils, 10^9^/L                                                       0.5                                           8                                             ---                                           4.5                                            ---                                           3.2                                          ---                                            1.4                                          ---
  Lymphocytes, 10^9^/L                                                       0.5                                           ---                                           ---                                           0.3                                            ---                                           0.7                                          ---                                            0.2                                          ---
  Creatinine, μmol/L                                                         102                                           47                                            68                                            60                                             55                                            116                                          72                                             83                                           118
  eGFR, mL/min/1.73 m^2^                                                     63                                            \>90                                          \>90                                          78                                             \>90                                          37                                           60                                             67                                           51
  M‐protein spike, g/L                                                       68                                            ---                                           16                                            0                                              1                                             2                                            ---                                            1                                            54
  IgG, g/L                                                                   1.8                                           2.2                                           0.83                                          5                                              3.0                                           4.9                                          5.7                                            8.1                                          0
  IgA, g/L                                                                   0                                             \<0.08                                        0                                             0.42                                           1.1                                           0.30                                         2.1                                            2.5                                          0.23
  IgM, g/L                                                                   \<0.1                                         \<0.08                                        \<0.1                                         0.96                                           \<0.1                                         0.24                                         0.34                                           0.39                                         0.21
  Immunoparesis[^g^](#ejh13502-note-0009){ref-type="fn"}                     Yes                                           Yes                                           Yes                                           Yes                                            Yes                                           Yes                                          Yes                                            No                                           Yes
  Clinical symptoms in the course of COVID‐19                                                                                                                                                                                                                                                                                                                                                                                                                
  Fever, \>38.5°C                                                            Yes                                           Yes                                           Yes                                           Yes                                            Yes                                           Yes                                          Yes                                            Yes                                          Yes
  Dry cough                                                                  Yes                                           No                                            Yes                                           Yes                                            Yes                                           Yes                                          Yes                                            Yes                                          Yes
  Dyspnoea                                                                   Yes                                           No                                            No                                            No                                             No                                            Yes                                          Yes                                            No                                           np
  Other COVID‐19 related symptoms[^h^](#ejh13502-note-0010){ref-type="fn"}   No                                            No                                            No                                            Yes                                            Yes                                           No                                           No                                             Yes                                          No
  Saturation, lowest level                                                   93%                                           ND                                            ND                                            95%[^i^](#ejh13502-note-0011){ref-type="fn"}   ND                                            89%                                          79%                                            70%                                          ND
  Oxygen demanding                                                           No                                            No                                            No                                            Yes                                            No                                            Yes                                          Yes                                            Yes                                          No
  Hospitalization                                                            No[^j^](#ejh13502-note-0012){ref-type="fn"}   No[^j^](#ejh13502-note-0012){ref-type="fn"}   No[^k^](#ejh13502-note-0013){ref-type="fn"}   Yes                                            No[^k^](#ejh13502-note-0013){ref-type="fn"}   Yes                                          Yes[^l^](#ejh13502-note-0014){ref-type="fn"}   Yes                                          No[^k^](#ejh13502-note-0013){ref-type="fn"}
  PCR and COVID‐19 specific IgG response                                                                                                                                                                                                                                                                                                                                                                                                                     
  Post‐COVID‐19‐positive PCR, d                                              NE                                            NE                                            ND                                            34                                             28                                            10                                           NE                                             NE                                           7
  IgG antibody response to COVID‐19, d                                       NE                                            NE                                            ND                                            46 (pos)                                       15 (neg)                                      10 (neg)                                     NE                                             NE                                           78 (neg)

Abbreviations: CR, complete response; dD, (daratumumab‐dexamethasone); dD‐Veneto, (daratumumab‐dexamethasone‐venetoclax); dKD, (daratumumab‐carfilzomib‐dexamethasone); DM2, Diabetes mellitus type 2; dRD, (daratumumab‐lenalidomide‐dexamethasone); dVD, (daratumumab‐bortezomib‐dexamethasone); HDT, (high‐dose treatment); HT, hypertension; KD, (carfilzomib‐dexamethasone); KPD, (carfilzomib‐pomalidomide‐dexamethasone); MR, minimal response; ND, not determined; NE, not evaluable due to exitus; PD, (pomalidomide‐dexamethasone); PD, progressive disease; PR, partial response; RD, (lenalidomide‐dexamethasone); VCD, (bortezomib‐cyclophosphamide‐dexamethasone); VGPR, very good partial response; VRD, (bortezomib‐lenalidomide‐dexamethasone); VTD, (bortezomib‐thalidomide‐dexamethasone).

As defined by the International Myeloma Working Group.

1st line VCD + HDT 2nd line RD 3rd line KPD 4th line dD 5th HDT.

1st line VTD 2nd line RD 3rd line PD, 4th line KD.

1st line VRD + HDT.

1st line VCD.

1st line VCD.

Reduction below the lower normal limit of one or two uninvolved immunoglobulins, IgG \< 6.7 g/L, IgA \< 0.88 g/L, IgM \< 0.27 g/L.

Either of diarrhea, arthralgia, loss of taste.

Saturation on 5 L oxygen.

Hospitalization was judged not to be beneficial, because of end‐stage disease.

Mild symptoms, admission to hospital not required.

Received oxygen treatment at home from advanced homecare teams.
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3. DISCUSSION {#ejh13502-sec-0004}
=============

Immunoparesis is associated with worse overall survival, which is not generally related to an increased risk of infections.[^9^](#ejh13502-bib-0009){ref-type="ref"}, [^11^](#ejh13502-bib-0011){ref-type="ref"} A report on patients with MM and COVID‐19 did not find a correlation between immunoparesis and increased risk of adverse COVID‐19 outcome.[^12^](#ejh13502-bib-0012){ref-type="ref"} However, in another report, higher mortality was reported in cases of severe IgG hypogammaglobulinemia, but not with immunoparesis.[^13^](#ejh13502-bib-0013){ref-type="ref"} In the present cohort, we observed immunoparesis in all daratumumab treated patients, but did not see a correlation with COVID‐19 outcome. Additional treatments, including previous high‐dose melphalan and autologous stem cell transplantation (ASCT), have not been associated with COVID‐19 severity.[^12^](#ejh13502-bib-0012){ref-type="ref"} Previous reports did not show a correlation between daratumumab or IMID‐based systemic therapy and adverse COVID‐19 outcome.[^13^](#ejh13502-bib-0013){ref-type="ref"}, [^14^](#ejh13502-bib-0014){ref-type="ref"} Only cardiovascular comorbidities were correlated with an increased odds ratio for hospitalization, ICU‐admission, mechanical ventilation, or death in the context of MM.[^12^](#ejh13502-bib-0012){ref-type="ref"}, [^13^](#ejh13502-bib-0013){ref-type="ref"} With mortality rates varying between 24% and 55%, patients with MM are more vulnerable to death from COVID‐19 compared to patients in the general population.[^12^](#ejh13502-bib-0012){ref-type="ref"}, [^13^](#ejh13502-bib-0013){ref-type="ref"}, [^14^](#ejh13502-bib-0014){ref-type="ref"} With the limitation of a low study subject number, we observed that patients with progressive disease seem to be at higher risk for mortality from COVID‐19 as were patients in remission on RD treatment. If confirmed by larger cohorts, this might be due to the dysregulation of the immune system during MM progression or the nature of immunomodulatory therapies. To address this, a detailed biomarker analysis including characterization of immune and inflammatory cell populations as well as pro‐inflammatory cytokines in patients with MM will be necessary.

In summary, based on previous reports and this study, patients with MM show a high risk for mortality from COVID‐19 infection which seems not to be associated with immunoparesis but rather immune dysregulation under progression or certain treatments such as RD. The exact underlying mechanisms are so far not understood. As there is currently no vaccine or specific treatments available, it is necessary to carefully consider clinical management and treatment of patients with MM in the context of COVID‐19.
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